XFOR News

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering